Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Puthanakit, Thanyawee; Nantanee, Rapisa; Jaru-Ampornpan, Peera; Chantasrisawad, Napaporn; Sophonphan, Jiratchaya; Meepuksom, Thutsanun; Jupimai, Thidarat; Sodsai, Pimpayao; Anugulruengkitt, Suvaporn; Hirankarn, Nattiya

doi:10.1016/j.jvacx.2022.100211

Cited by 7 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse events reported herein were similar to those of pain, myalgia, and fever described in the previous studies. 2, 22…”

Section: Discussionmentioning

confidence: 99%

“…The adverse events reported herein were similar to those of pain, myalgia, and fever described in the previous studies. 2,22 Nearly one-third of the participants in the CoronaVac/BNT162b2 group had been exposed to the SARS-CoV-2 virus prior to enrollment. This was detected by seropositivity of anti-nucleocapsid (N) IgG or total RBD Ig at baseline.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

Wanlapakorn¹,

Kanokudom

Phowatthanasathian

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5-11 years of age. Methods: A prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5-11 years of age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP-CorV between 1-3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster). Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity analysis was performed to determine binding and surrogate neutralizing antibodies to SARS-CoV-2 wild-type and Omicron variants. Results: Overall, 166 eligible children were enrolled. Local and systemic AE which occurred within 7 days after vaccination were mild to moderate and well-tolerated. At one-month, post-two or post-three doses, children vaccinated with two-dose BNT162b2, CoronaVac/BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 elicited similar levels of anti-receptor-binding domain (RBD) IgG. However, the two-dose BNT162b2 and two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities against Omicron BA.2 variant than the CoronaVac/BNT162b2 group. Conclusion: The heterologous, CoronaVac vaccine followed by the BNT162b2 vaccine, regimen elicited lower neutralizing activities against the emerging Omicron BA.2 variant than the two-dose mRNA regimen. A third dose (booster) mRNA vaccine should be prioritized for this group.

show abstract

“…The adverse events reported herein were similar to those of pain, myalgia, and fever described in the previous studies. 2, 22…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

Wanlapakorn¹,

Kanokudom

Phowatthanasathian

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The heterologous prime-boost approach, by boosting children who received one dose of inactivated vaccines with an mRNA vaccine, has been studied. 60 Although there was no control group that received two doses of inactivated vaccines, adolescents who received 2-dose primary series of CoronaVac-BNT162b2 had high sVNT against the Delta variant that persisted at five months after the second dose. Using another approach, our group explored whether full-dose intradermal vaccination could result in superior immunogenicity, based on the rationale that fractional-dose intradermal administration of vaccines against other viruses could elicit comparable immunogenicity to the intramuscular injection route.…”

Section: Inactivated Virus Vaccinesmentioning

confidence: 99%

“…Several teams investigated ways to improve the immunogenicity of inactivated vaccines. The heterologous prime‐boost approach, by boosting children who received one dose of inactivated vaccines with an mRNA vaccine, has been studied 60 . Although there was no control group that received two doses of inactivated vaccines, adolescents who received 2‐dose primary series of CoronaVac‐BNT162b2 had high sVNT against the Delta variant that persisted at five months after the second dose.…”

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 99%

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Leung

Duque

et al. 2023

Pediatric Discovery

View full text Add to dashboard Cite

SARS‐CoV‐2 causes millions of infection cases and coronavirus disease 2019 (COVID‐19)‐related deaths worldwide. In addition to acute illnesses, children and adolescents suffer from post‐infectious complications. Vaccination is a promising preventative treatment that can confer protection from these devastating outcomes. Utilizing ChatGPT, this review discusses the immunogenicity of mRNA and inactivated COVID‐19 vaccines in children and adolescents. Rapid vaccine discovery during the COVID‐19 pandemic led to the approval of the mRNA vaccines that stimulate potent antibody responses in pediatric population, and the younger age groups develop higher neutralizing and non‐neutralizing antibody responses than those who are older. Natural infection induces weaker antibody responses than vaccination. Vaccine‐induced humoral immunity decreases over time, as antibodies decline six months after the second dose. However, antibody avidity increases, which partly maintains neutralization and Fc‐effector functions that provide more durable protection. Inactivated COVID‐19 vaccines generate strong antibody responses in children and adolescents. They induce T cell responses against multiple structural protein antigens, although their neutralizing antibody responses appear weaker and wane more quickly than mRNA vaccines. Full‐dose intradermal administration and heterologous prime‐boost may improve the immunogenicity of inactivated vaccines. In children and adolescents, immune protection from the pre‐Omicron variants of concern (VOCs) is maintained. Vaccination induces less antibody neutralization against the Omicron variant, but non‐neutralizing antibodies and T cell responses persist. Hybrid immunity provides stronger immunogenicity against SARS‐CoV‐2 in the pediatric population. Future research must focus on long‐term immunity, interaction with breakthrough reinfections, cross‐reactivity against new VOCs, T cell immunogenicity and immunogenicity in young children.

show abstract

“…The AE reported herein were similar to those of pain, myalgia, and fever described in the previous studies. 2,25 Nearly one-third of the participants in the CoronaVac/ subjects immunized with one-dose BNT162b2 vaccine, but this difference disappeared after the second dose vaccine. This is also in agreement with a previous study in adults which showed that previously infected vaccinees who received 2 doses mRNA vaccine elicited higher Omicron BA.1-specific neutralizing antibodies similar to the triple-vaccinated subjects, but higher than SARS-CoV-2 naïve subjects who received 2 doses mRNA vaccine.…”

Section: Total Rbd Ig and Anti-rbd Igg Responses Between Two-dose Vac...mentioning

confidence: 99%

Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years

Wanlapakorn

Kanokudom

Phowatthanasathian

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

To compare the reactogenicity and immunogenicity between the two-dose mRNA COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5 and 11 years of age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5 and 11 years of age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP-CorV between 1 and 3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster). Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity analysis was performed to determine binding antibodies to wild-type SARS-CoV-2. Neutralizing antibodies to Omicron variants (BA.2 and BA.5) were tested using the focus reduction neutralization test. Overall, 166 eligible children were enrolled. Local and systemic adverse events which occurred within 7 days after vaccination were mild to moderate and well-tolerated.The two-dose BNT162b2, CoronaVac followed by BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 groups elicited similar levels of anti-receptorbinding domain (RBD) IgG. However, the two-dose BNT162b2 and two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities against the Omicron BA.2 and BA.5 variant than the CoronaVac followed by

show abstract

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Cited by 7 publications

References 28 publications

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years

Contact Info

Product

Resources

About